Can Goserelin Be Given with Capecitabine?
Yes, goserelin can be safely administered concurrently with capecitabine. There are no documented drug-drug interactions between these agents, and clinical guidelines explicitly support their concurrent use in specific clinical scenarios.
Evidence Supporting Concurrent Use
The most direct evidence comes from breast cancer treatment guidelines. In premenopausal patients with hormone-responsive breast cancer receiving chemotherapy (including capecitabine-containing regimens), gonadotropin-releasing hormone analogues like goserelin can be started concurrently with chemotherapy, leading to rapid amenorrhea 1. This recommendation appears in ESMO guidelines for primary breast cancer management.
The 2025 NCCN Breast Cancer Guidelines further clarify the sequencing: while most chemotherapy agents should be given sequentially with other systemic therapies, capecitabine is typically given after completion of radiation therapy but can be coordinated with endocrine therapy including GnRH agonists 2. The guidelines make no mention of contraindications or concerns regarding concurrent goserelin use.
Clinical Context and Rationale
When This Combination Is Used
This combination is most relevant in two scenarios:
Ovarian protection during chemotherapy: Goserelin (3.6 mg subcutaneously monthly) is used to induce reversible ovarian suppression in premenopausal women receiving chemotherapy 1. Research demonstrates that goserelin co-administration with chemotherapy provides ovarian reserve protection, with significantly higher AMH recovery rates (46.5% vs 21.8%) compared to chemotherapy alone 3.
Endocrine therapy in hormone-receptor-positive disease: For premenopausal patients with hormone-responsive tumors, goserelin serves as ovarian suppression while capecitabine may be part of the chemotherapy regimen 1.
Pharmacologic Considerations
There are no pharmacokinetic or pharmacodynamic interactions between goserelin and capecitabine. The FDA label for capecitabine extensively details drug interactions, including specific warnings about warfarin, phenytoin, and CYP2C9 substrates 4. Goserelin is notably absent from these interaction warnings, indicating no clinically significant interaction.
Goserelin works via pituitary GnRH receptor agonism leading to ovarian suppression, while capecitabine is a prodrug converted to 5-FU through enzymatic pathways. These mechanisms do not overlap 4.
Important Caveats
Timing Considerations
- Start goserelin at least 1 week before the first cycle of chemotherapy when used for ovarian protection, then continue every 4 weeks throughout chemotherapy duration 3
- Goserelin should be given for at least 2 years when used for endocrine therapy, though optimal duration is not fully established 1
Monitoring Requirements
While the combination is safe, patients on capecitabine require standard monitoring for:
- Hand-foot syndrome (grade 2 or higher requires immediate cessation) 4
- Diarrhea, nausea, vomiting (grade 2 or higher requires stopping capecitabine) 4
- If the patient is also on anticoagulants like warfarin, extremely close INR monitoring is mandatory as capecitabine significantly increases warfarin effect (91% increase in maximum INR observed), with interactions persisting up to 1 month after stopping capecitabine 4, 5
Population-Specific Considerations
- Premenopausal women are the primary population for concurrent goserelin-capecitabine use 1
- Patients should take capecitabine within 30 minutes after meals 4
- Women of childbearing potential should avoid pregnancy during capecitabine treatment 4
The combination of goserelin and capecitabine is both safe and clinically appropriate, particularly in premenopausal breast cancer patients requiring chemotherapy with concurrent ovarian protection or endocrine therapy.